Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma  by Khan, S.A. et al.
REVIEW ARTICLE
Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma
S. A. KHAN1, M. B. TOLEDANO2 & S. D. TAYLOR-ROBINSON1
1Department of Hepatology and Gastroenterology and 2Department of Epidemiology and Public Health, Imperial College
London, London, UK
Abstract
Cholangiocarcinoma (CCA) is a fatal cancer of the biliary epithelium, arising either within the liver (intrahepatic, ICC) or in
the extrahepatic bile ducts (extrahepatic ECC). Globally, CCA is the second most common primary hepatic malignancy.
Several recent epidemiological studies have shown that the incidence and mortality rates of ICC are increasing. This review
of the literature on the international epidemiological rates of CCA, both intra- and extrahepatic, explores possible
explanations for the trends found. The possible role of epidemiological artifact in the findings is discussed and the known
risk factors for CCA are summarized. These include primary sclerosing cholangitis, liver fluke infestation, congenital
fibropolycystic liver, bile duct adenomas, and biliary papillomatosis, hepatolithiasis, chemical carcinogens such as
nitrosamines, Thorotrast, chronic viral hepatitis, cirrhosis, chronic non-alcoholic liver disease and obesity. Potential
pathways involved in the molecular pathogenesis of CCA are also summarized.
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Introduction
Cholangiocarcinoma (CCA) is a fatal cancer of the
biliary epithelium, arising either within the liver
(intrahepatic) or in the extrahepatic bile ducts (extra-
hepatic). Globally, CCA is the second most common
primary hepatic malignancy. Several recent epidemio-
logical studies have shown that incidence and mor-
tality rates of intrahepatic CCA are increasing [18].
Most time-trend studies have covered periods when
mortality or incidence data were coded to the 8th or
9th revisions of the International Classification of
Diseases (ICD). In these revisions, tumors with
histology ‘cholangiocarcinoma’ (‘CCA’) were not
coded to any specific topography. Hence, the data
analyzed in these studies actually reflect time trends in
the topographical codes for ‘intrahepatic bile duct
tumors’ (IHBT). These tumors will not all have
‘CCA’ histology and, moreover, not all intrahepatic
CCAs will be coded topographically as IHBT, but,
rather, in ICD8 and 9 were also classified topogra-
phically as ‘primary liver tumors’. Since the 10th
revision of the ICD was introduced into mortality
statistics (in 2001 in the UK), all intrahepatic CCAs
are specifically coded to the IHBT (C22.1) topogra-
phical code.
Changing epidemiology of cholangiocarcinoma
The peak age for CCA is the seventh decade, with a
slightly higher incidence in men [1]. Given the poor
prognosis of CCA, mortality and incidence rates are
similar. CCA incidence rates vary markedly world-
wide, presumably reflecting differences in local risk
factors and genetics. The highest rates are in north-
east Thailand (96 per 100,000 men) and are about
100 times greater than in the West [1]. The rise in
IHBTs was first reported in the United Kingdom,
where, in the mid-1990s, they overtook hepatocellular
carcinoma as the leading cause of death for primary
liver cancer [2,5,7]. From 1968 to 2001, age-standar-
dized mortality rates (ASMR per 100,000 population)
for IHBT increased from 0.10 to 1.49 in males (M)
and from 0.05 to 1.24 in females (F). The annual total
number of deaths rose almost 30-fold, from 36 in
1968 to 1003 in 2004. Between 1979 and 2000, age
standardized incidence rates (ASIR/100,000 popula-
tion) increased from 0.11 to 1.2 (F) and from 0.13 to
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1.36 (M). Age-specific incidence rates were highest in
those over 75 years of age [6]. Between 1971 and
2001 the incidence of gallbladder cancer halved and
extrahepatic biliary tumors (EHBT) fell by a third in
the UK [7].
Further epidemiological studies have shown that
mortality rates of IHBT are rising, while those of
EHBTare falling, globally. World Health Organization
mortality data were examined for the US, UK, France,
Italy, Japan and Australia, 19791998 [2]. ASMR for
IHBT increased in both sexes in all countries (Figure
1b), except in Japanese women. The highest increases
were in Australia (M, 0.1 to 0.7) and the UK (0.2 to
0.83). Conversely, ASMR for EHBT decreased in
most countries (such as the USA: 1.1 to 0.7), the
exceptions being Italy and Japan (Figure 1c). Another
study of the WHO databank calculated estimated
annual percentage changes (EAPC) in age-adjusted
mortality rates from 22 countries (Table I) [4]. All
major world regions were represented, other than
Africa, where consecutive data were unavailable.
EAPC for IHBT increased in both sexes in all countries
except two: Norway and the Czech Republic, which
had data available for the smallest time period (less
than 8 years). The range of EAPC increases was 1.5
(Hungarian men) to 22 per 100,000 population
(Slovenian men). There was an increase in IHBT
mortality in all geographical regions: the Americas,
Oceania, and across Europe, particularly western
compared with central and northern Europe. In all
countries, with the exception of Japan and Greece,
EAPC for EHBT had fallen or remained stable (Table
I, Figure 2) [4]. A US study examined trends in IHBT
incidence using data from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program, which repre-
sents over 10% of the total US population. Data from
19762000 were analysed by age, gender, and ethni-
city. Intrahepatic CCA incidence increased in all
groups, but was highest in black men (139%), followed
by white men (124%), white women (111%), and
black women (86%) [8].
In contrast to the above investigations, none of
which included Denmark, a recent study of Danish
Cancer Registry data between 1978 and 2002 showed
a fall in incidence rates of both IHBT (1.27 to 0.46
per 100,000 population) and EHBT (1.05 to 0.74).
This occurred across all age groups and in both sexes
[9].
Potential epidemiological artifact?
Does the rise in intrahepatic CCA incidence rates
represent a real increase in this tumor? In a study of
the SEER database it was found that age-adjusted
incidence rates of IHBT increased by 165%, i.e. from
0.32/100,000 in 19751979 to 0.85/100,00 in 1995
1999 [10]. Increased detection of a tumor is usually
associated with an increase in the proportion of
patients with early stage disease or smaller sized
lesions. The rise in IHBT was not associated with
either. Furthermore, the increase in IHBT incidence
has not levelled off, as would be expected if it was
secondary to improvement in diagnostic techniques,
Figure 1. Mortality trends in men from 1979 onwards for: (a) ICD-
9 155.0 (primary hepatic parenchymal cancer, including hepato-
cellular carcinoma, HCC), (b) 155.1 (ICC) and (c) 156 (tumors of
the gallbladder and ECC). Source: Khan et al. J Hepatol
2002;37:80613.
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such as ERCP, MRI, or CT, which have become
established practice for several years [2,5,11]. The
data on EHBT may be more difficult to determine, as
gallbladder cancers have previously been combined
with EHBT for ICD coding purposes, which is
revised on a regular basis. Gallbladder cancers are
known to be decreasing, probably as a result of
increasing cholecystectomy rates over the past few
decades [2,5,11]. This may partly explain falling rates
of tumors coded as EHBT.
Another potential source of artifact is misclassifica-
tion of hilar (Klatskin) tumors. Although these are
topographically extrahepatic, the second edition of
ICD-0-2 assigned them a histology code ‘‘8162/3,
Klatskin’’, which was cross-referenced to intrahepatic
CCA. A recent study examined the impact of this
misclassification of hilar (Klatskin) CCA on reported
incidence rates [12]. Annual percentage changes
(APCs) were calculated with data from the SEER
program. During 19922000, when SEER used ICD-
O-2, 91% of hilar CCAs were incorrectly coded as
intrahepatic CCA, resulting in an overestimation of
intrahepatic CCA incidence by 13% and underesti-
mation of extrahepatic CCA incidence by 15%.
However, even after the exclusion of tumors that
were coded as Klatskin, age-adjusted annual intrahe-
patic CCA incidence still increased (APC4%; pB
0.001) [12].
Overall, incidence rates of IHBTs appear to be
rising in most countries studied. This is not explained
by any observed change in the incidence of known risk
factors. Although the reason for the rise in IHBT
remains unclear, the heterogeneity in rates with
respect to regions, gender, and ethnicity suggests
that the rise is likely, at least in part, to reflect a
genuine increase in these tumors. The heterogeneity
in rates between different regions, sexes, and ethnic
groups suggests the increase in CCA is genuine.
Most cases of CCA are sporadic, and recognized
risk factors account for a minority of cases. Given that
CCA has risen in a relatively short period of time, an
environmental factor is likely to play a role in
carcinogenesis. Environmental carcinogens are unli-
kely to be evenly distributed geographically and would
be expected to give rise to spatial patterns, or
clustering, of CCA risk. Preliminary data from the
UK support this. A spatio-temporal analysis of
intrahepatic biliary tract mortality, at the District
level, between 1981 and 2004, showed strong evi-
dence of spatial clustering, particularly in rural areas
with a high proportion of agricultural land use [13].
Table I. Trends in mortality from intrahepatic and extrahepatic biliary tract cancers, WHO Databank (EAPCestimated annual percent
change in age-adjusted mortality rates). Source: Patel. BMC Cancer 2002;2:10.
Extrahepatic tumors Intrahepatic tumors
EAPC EAPC
Region Country Years Male Female Years Male Female
Americas Canada 19701997 1.9 2.8 19791997 7.9 8.8
USA 19701996 2.5 2.8 19791997 7.3 8.5
Oceania Australia 19701995 1.9 1.9 19791995 12.3 12.0
New Zealand 19701996 2.7 3.1 19791996 4.4 3.4
Western Europe Austria 19701998 1.5 2.7 19801998 6.0 5.2
Belgium 19701994 1.5 2.5
Former FDR 19701990 0.9 1.8
France 19701996 1.2 0.1 19831996 10.0 5.2
Germany 19901997 1.2 3.2 19911997 13.2 2.5
Greece 19701997 3.2 2.2 19791997 1.8 2.4
Ireland 19701996 0.5 2.5 19791996 10.9 8.5
Italy 19701995 2.9 2.3 19861995 4.2 5.9
Netherlands 19701995 2.3 3.9 19791995 3.5 0.2
Portugal 19841998 1.7 0.1 19841996 10.4 10.3
Spain 19701994 2.9 3.0 19821995 18.3 12.7
UK 19701996 3.7 3.1 19791997 8.8 9.6
Central Europe Czech 19861993 0.3 2.2 19861993 8.5 5.6
Former Czech 19701991 1.4 0.6
Former GDR 19761990 0.5 1.9
Hungary 19701995 1.1 0.6 19791995 1.5 2.1
Slovenia 19851996 1.3 2.5 19881996 22.1 10.3
Northern Europe Iceland 19711995 2.1 2.3
Norway 19701995 0.1 0.9 19891995 3.0 2.5
Sweden 19701995 0.6 0.5 19871996 9.1 3.5
Asia/Middle East Israel 19701991 3.9 4.4 19871996 3.1 2.9
Japan 19701994 3.2 2.4 19791994 7.4 0.9
Singapore 19701996 1.7 1.0 19791998 6.1 6.0
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Risk factors and pathogenesis for
cholangiocarcinoma [11,14,15]
Bile duct factors
Primary sclerosing cholangitis (PSC) is the common-
est known predisposing factor for CCA in the West.
CCA rates of up to 40% have been reported in PSC
patients [1]. In East Asia, where the disease is
common, CCA has been pathogenically associated
with liver fluke infestation, particularly the endemic
Opisthorcis viverrini [1,16]. Malignant change in the
biliary epithelium of Syrian hamsters occurs following
infection with O. viverrini, particularly if fed nitrosa-
mines, which are known carcinogens produced by
bacteria in certain foodstuffs [17]. Congenital fibro-
polycystic liver disease carries a 15% risk of malignant
change, the average age being 34 years [18]. Bile duct
adenomas and biliary papillomatosis are also asso-
ciated with CCA risk.
Up to 10% of patients with intrahepatic biliary
stones develop CCA [19]. Relatively rare in the West,
hepatolithiasis is common in parts of Asia and is
associated with intrahepatic CCA [1]. A Taiwanese
study found that up to 70% of patients undergoing
resection for CCA had hepatolithiasis [20,21]. Chole-
docholithiasis (odds ratio, OR, 24) and cholecysto-
lithiasis (OR 4.0) were associated with an increased risk
of CCA in a recent Danish case-control study [22].
Other factors
Various chemicals have been linked to CCA. The
banned carcinogenic contrast agent Thorotrast has
been strongly associated with CCA, in some cases
many years after exposure [23]. Epidemiological
associations have been made to industrial toxins such
as dioxins and nitrosamines [24]. Excess alcohol was
higher in intrahepatic CCA (22%) compared to con-
trols (4%) in a recent US case-control study [25]. This
study found no difference in the prevalence of diabetes
and smoking. In another US case-control study,
significantly higher rates of thyrotoxicosis, chronic
pancreatitis, non-specific liver cirrhosis, and alcohol
were found in both extrahepatic CCA and intrahepatic
CCA compared to controls. Higher rates of HCV
infection, chronic non-alcoholic liver disease, and
obesity (all of which are increasing in incidence) were
associated with intrahepatic CCA only, suggesting that
Figure 2. Regional differences in the mean estimated annual percentage change in age-adjusted (1970 World Standard population) gender-
specific mortality rates from intrahepatic biliary tract tumors (top) and gallbladder and extrahepatic biliary tract tumors (bottom). Source:
Patel BMC Cancer 2002;2:10.
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different conditions might explain the divergent in-
cidence trends of intrahepatic CCA and extrahepatic
CCA [26]. This study found that smoking was
associated with intrahepatic CCA.
Cirrhosis from any cause is associated with an
increased risk of CCA [26,27]. In a cohort study of
over 11,000 patients with cirrhosis followed up over 6
years, a 10-fold excess risk of CCA was found
compared to the general population [27]. Hepatitis B
(HBV) and hepatitis C (HCV) are established risk
factors for hepatocellular carcinoma and may have a
role in cholangiocarcinogenesis. In a Korean case-
control study, 13% of CCA cases were found positive
for anti-HCV and 14% for HBV surface antigen
(HBsAg), compared to 4% and 2% of controls,
respectively [28]. In a study from Italy, 23% of CCA
patients were found anti-HCV positive and 11.5%
HBsAg positive compared with 6% and 5.5% of
controls [29]. A Japanese prospective controlled study
found the risk of CCA in HCV-related cirrhosis to be
3.5% after 10 years, 1000 times greater than in the
general population [30]. A case-control study from the
US reported adjusted OR of 6 for HCV infection, and
similarly for HIV [31]. In another US study, a higher
prevalence of anti-HCV antibodies and antibodies to
Hepatitis B core antigen (anti-HBc) was found in
intrahepatic CCA cases (6% and 9.6%, respectively)
compared to controls (0.8% and 0%) [25].
Molecular pathogenesis of
cholangiocarcinogenesis
Differences in geographical rates, gender, race, and
risk factors suggest diverse mechanisms are likely to
be involved in the multi-step development of CCA
[11,14]. Chemically associated carcinogenesis may
involve the induction of promutagenic DNA adducts,
which occur more commonly in CCA tissue com-
pared to controls [32]. The main hepatobiliary risk
factors all tend to cause chronic inflammation and/or
cholestasis in the bile duct. At the molecular level,
cholangiocarcinogenesis is probably triggered by
changes in the bile duct microenvironment secondary
to these events (Table II) [14].
Consensus statements
. Incidence rates of intrahepatic bile duct tumors
appear to be rising in most countries studied.
The heterogeneity in rates with respect to re-
gions, gender, and ethnicity suggests that the rise
is likely, at least in part, to reflect a genuine
increase in this tumor.
. There should be international consistency in the
diagnosis and topographical and morphological
classification of all bile duct tumors to facilitate
accurate surveillance of future epidemiological
trends.
. Further studies are required into the etiopatho-
genesis of CCA.
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